Developing Allosteric Chaperones for GBA1-Associated Disorders—An Integrated Computational and Experimental Approach
International Journal of Molecular Sciences · 24.12.2024 · 26 (1) · 9
DOI: 10.3390/ijms26010009 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.12.2024. Verfasst von Marta Montpeyo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Network Center for Biomedical Research in Neurodegenerative Diseas…. Hauptthemen laut MEDLINE: Glucosylceramidase, Gaucher Disease, Molecular Chaperones. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation & Silverstein Foundation, Eurostars-2 joint program, MINECO (Spain).
Abstract (Originalsprache)
Mutations in the GBA1 gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase), are associated with Gaucher disease and increased risk of Parkinson’s disease. This study describes the discovery and characterization of novel allosteric pharmacological chaperones for GCase through an innovative computational approach combined with experimental validation. Utilizing virtual screening and structure-activity relationship optimization, researchers identified several compounds that significantly enhance GCase activity and stability across various cellular models, including patient-derived fibroblasts and neuronal cells harboring GBA1 mutations. Among these, compound 3 emerged as a lead candidate, demonstrating the ability to enhance GCase protein levels and enzymatic activity while effectively reducing the accumulation of toxic substrates in neuronal models. Importantly, pharmacokinetic studies revealed that compound 3 has favorable brain penetration, indicating its potential as a disease-modifying therapy for GBA1-related disorders affecting the central nervous system. This research not only offers a framework for developing allosteric GCase modulators but also unveils promising new therapeutic strategies for managing Gaucher disease and Parkinson’s disease. The ability of compound 3 to cross the blood-brain barrier emphasizes its potential significance in addressing neurological symptoms associated with these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 08035 Barcelona, Spain.
- Gain Therapeutics Sucursal en España, Parc Científic de Barcelona, 08028 Barcelona, Spain.
- GT Gain Therapeutics SA, 6900 Lugano, Switzerland.
ORCID-Profile: Elena Cubero, Aida Delgado, Marta Martinez-Vicente, Ana Maria Garcia-Collazo
Förderung
- Michael J. Fox Foundation & Silverstein Foundation
- Eurostars-2 joint program
- MINECO (Spain)
- Instituto de Salud Carlos III, EU/Spain
- Michael J. Fox Foundation
- Eureka|Eurostars
Zitieren
APA
Montpeyo, M., Pérez-Carmona, N., Cubero, E., Delgado, A., Ruano, A., Carrillo, J., Bellotto, M., Martinez-Vicente, M., & Garcia-Collazo, A. M. (2024). Developing Allosteric Chaperones for GBA1-Associated Disorders—An Integrated Computational and Experimental Approach. International Journal of Molecular Sciences, 26(1), 9. https://doi.org/10.3390/ijms26010009
Vancouver
Montpeyo M, Pérez-Carmona N, Cubero E, Delgado A, Ruano A, Carrillo J, et al. Developing Allosteric Chaperones for GBA1-Associated Disorders—An Integrated Computational and Experimental Approach. International Journal of Molecular Sciences. 2024;26(1):9. doi:10.3390/ijms26010009
BibTeX
@article{Montpeyo2024,
author = {Montpeyo, Marta and Pérez-Carmona, Natàlia and Cubero, Elena and Delgado, Aida and Ruano, Ana and Carrillo, Jokin and Bellotto, Manolo and Martinez-Vicente, Marta and Garcia-Collazo, Ana Maria},
title = {Developing Allosteric Chaperones for GBA1-Associated Disorders—An Integrated Computational and Experimental Approach},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {26},
number = {1},
pages = {9},
doi = {10.3390/ijms26010009}
}
EUVIMED